Skip to main content
Passage BIO, Inc. logo

Passage BIO, Inc. — Investor Relations & Filings

Ticker · PASG ISIN · US7027121000 US Professional, scientific and technical activities
Open in API
Filings indexed 414 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country US United States of America
Listing US PASG

About Passage BIO, Inc.

https://www.passagebio.com/

Passage Bio, Inc. is a clinical-stage genetic medicines company focused on developing therapies for central nervous system (CNS) disorders. The company develops a portfolio of adeno-associated virus (AAV)-delivered therapeutics designed to treat rare, monogenic neurodegenerative diseases by delivering functional genes to patients with mutated or nonfunctional ones. Its lead clinical program, PBFT02, is a gene therapy being evaluated in a Phase 1/2 study for the treatment of Frontotemporal Dementia (FTD) with progranulin gene (GRN) mutations. Passage Bio aims to advance its pipeline to redefine the course of neurodegenerative conditions for patients.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 86% confidence The document is a Form 8-K “Current Report” filed with the SEC to disclose the termination of material definitive agreements. It is not an annual or interim financial report, earnings release, or any specialized transaction category. It is therefore a general regulatory filing under the Exchange Act, making Regulatory Filings (RNS) the correct classification.
2026-05-27 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an SEC Form 8-K “Current Report” dated May 19, 2026, disclosing Item 5.07: Submission of Matters to a Vote of Security Holders, including detailed vote tallies for director elections, auditor ratification, and advisory votes. This matches the category for official results from shareholder votes at a general meeting, therefore it is classified as Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-26 English
10-Q - Passage BIO, Inc. (0001787297) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-12 English
8-K - Passage BIO, Inc. (0001787297) (Filer)
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 28, 2026, by Passage Bio, Inc. It announces a restructuring plan involving workforce reduction and associated costs. The content focuses on a specific event (restructuring and related costs) rather than comprehensive financial results or detailed financial statements. It is not an annual or quarterly report, audit report, earnings release, or any other detailed financial report. The document is a regulatory announcement of a material event affecting the company, typical of Form 8-K filings. Therefore, it fits best under Regulatory Filings (RNS).
2026-04-28 English
8-K - Passage BIO, Inc. (0001787297) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes updated interim clinical trial data, regulatory updates, and a corporate update about a strategic review process. It explicitly states it is a Current Report pursuant to the Securities Exchange Act of 1934. The document does not contain full financial statements or comprehensive financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). It also does not fit categories like Earnings Release (ER) or Management Reports (MDA) because it focuses on clinical and corporate updates rather than detailed financial results. The presence of a corporate presentation as an exhibit suggests investor communication but the main document is a regulatory filing announcing material events. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2026-04-20 English
ARS - Passage BIO, Inc. (0001787297) (Filer)
Annual Report
2026-04-07 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.